Pancreatic neuroendocrine tumor (pNET), well-differentiated G1/G2 · line 1 · Everolimus monotherapy (advanced/progressive pNET G1/G2; RADIANT-3)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-EVEROLIMUS-MONO-PNET |
| ID | IND-PNET-METASTATIC-1L-EVEROLIMUS |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-03 | pending_clinical_signoff |
| Diseases | DIS-PNET |
| Sources | SRC-NCCN-NET-2025 SRC-RADIANT3-YAO-2011 |
Notes
STUB — requires clinical co-lead signoff (CHARTER §6.1 dev-mode exemption). Sunitinib indication (IND-PNET-METASTATIC-1L-SUNITINIB) deferred — DRUG-SUNITINIB entity created, regimen and indication to be authored as follow-up PR. SSA concurrent use (octreotide/lanreotide): ~50% of RADIANT-3 patients were on SSA at baseline; concurrent use is allowed and may provide additive antiproliferative + symptomatic benefit.
Used By
Algorithms
ALGO-PNET-METASTATIC-1L- ALGO-PNET-METASTATIC-1L